Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057265
Status:
COMPLETED
Last Update Posted:
2015-03-20
First Post:
2003-03-28
Brief Title:
A Randomized Double Blind Trial of LdT Telbivudine Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double Blind Trial of LdT Telbivudine Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being conducted to compare the safety and effectiveness of the investigational medication LdT Telbivudine with Lamivudine a drug currently approved by the US European and Asian Health Authorities for the treatment of hepatitis B infection The results for patients taking LdT will be compared to results for patients taking Lamivudine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None